- Home
- TNGX vs PHLT Comparison
TNGX vs PHLT Comparison
Compare TNGX & PHLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- PHLT
- Stock Information
- Founded
- TNGX 2014
- PHLT 1976
- Country
- TNGX United States
- PHLT United States
- Employees
- TNGX N/A
- PHLT N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- PHLT Other Consumer Services
- Sector
- TNGX Health Care
- PHLT Consumer Discretionary
- Exchange
- TNGX Nasdaq
- PHLT Nasdaq
- Market Cap
- TNGX 723.2M
- PHLT 612.2M
- IPO Year
- TNGX N/A
- PHLT N/A
- Fundamental
- Price
- TNGX $8.76
- PHLT $7.75
- Analyst Decision
- TNGX Strong Buy
- PHLT Buy
- Analyst Count
- TNGX 6
- PHLT 2
- Target Price
- TNGX $10.00
- PHLT $7.88
- AVG Volume (30 Days)
- TNGX 2.1M
- PHLT 777.5K
- Earning Date
- TNGX 11-06-2025
- PHLT 11-04-2025
- Dividend Yield
- TNGX N/A
- PHLT N/A
- EPS Growth
- TNGX N/A
- PHLT N/A
- EPS
- TNGX N/A
- PHLT N/A
- Revenue
- TNGX $24,296,000.00
- PHLT $137,357,000.00
- Revenue This Year
- TNGX $20.42
- PHLT $12.38
- Revenue Next Year
- TNGX N/A
- PHLT $10.09
- P/E Ratio
- TNGX N/A
- PHLT N/A
- Revenue Growth
- TNGX N/A
- PHLT 15.21
- 52 Week Low
- TNGX $1.03
- PHLT $2.17
- 52 Week High
- TNGX $9.70
- PHLT $7.76
- Technical
- Relative Strength Index (RSI)
- TNGX 58.17
- PHLT 74.58
- Support Level
- TNGX $8.85
- PHLT $7.72
- Resistance Level
- TNGX $9.31
- PHLT $7.75
- Average True Range (ATR)
- TNGX 0.56
- PHLT 0.02
- MACD
- TNGX 0.08
- PHLT -0.04
- Stochastic Oscillator
- TNGX 67.60
- PHLT 83.33
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About PHLT Performant Healthcare Inc. Common Stock
Performant Healthcare Inc provides solutions to payers in the healthcare industry to identify, prevent, and recover waste and improper payments by leveraging technology, analytics, and proprietary data assets.